| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BPC INSTRUMENTS Aktie jetzt für 0€ handeln | |||||
| Do | BPC INSTRUMENTS AB: BPC Instruments secures new order for several BPC Go units from an international energy group | 2 | Cision News | ||
| Do | BPC Instruments AB: BPC Instruments secures new order for several BPC Go units from a international energy group | 380 | PR Newswire | LUND, Sweden, Nov. 20, 2025 /PRNewswire/ -- BPC Instruments AB (publ) has received a new order valued at approximately SEK 0.9 million for several BPC Go units from a major international... ► Artikel lesen | |
| 12.11. | BPC Instruments AB: BPC Instruments reports results for the period January - September 2025 | 709 | PR Newswire | LUND, Sweden, Nov. 12, 2025 /PRNewswire/ -- BPC Instruments AB (publ) hereby publishes the interim report for the period January 1 - September 30, 2025. The interim report is available... ► Artikel lesen | |
| 10.09. | BPC INSTRUMENTS AB: BPC Instruments launches consultation and training service to strengthen customer value | 1 | Cision News | ||
| 02.09. | BPC Instruments AB: BPC Instruments expands into the textile sector - receives order from a global materials company | 250 | PR Newswire | LUND, Sweden, Sept. 2, 2025 /PRNewswire/ -- BPC Instruments AB (publ) is extending the industrial application of its BPC® Blue platform into the textiles & apparel sector, broadening the... ► Artikel lesen | |
| 27.08. | BPC Instruments AB: BPC Instruments reports results for H1 and Q2 2025 | 438 | PR Newswire | LUND, Sweden, Aug. 27, 2025 /PRNewswire/ -- BPC Instruments (publ) hereby publishes the half-year report for the period January 1 - June 30, 2025. The half-year report is available as an... ► Artikel lesen | |
| 05.08. | BPC Instruments AB: BPC Instruments secures 4.4 MSEK order from a public research organisation in the Philippines | 339 | PR Newswire | LUND, Sweden, Aug. 5, 2025 /PRNewswire/ -- BPC Instruments AB (publ) has received an order valued at approximately SEK 4.4 million from a public research institution in the Philippines, operating... ► Artikel lesen | |
| 21.07. | BPC Instruments AB: BPC Instruments receives order from Cornell University of 1 MSEK | 274 | PR Newswire | LUND, Sweden, July 21, 2025
/PRNewswire/ -- BPC Instruments AB (publ) has received an order from Cornell University in the United States valued at approximately SEK 1 million. The order... ► Artikel lesen | |
| 04.06. | BPC Instruments AB: BPC Instruments receives orders from KU Leuven valued at 0.7 MSEK | 316 | PR Newswire | LUND, Sweden, June 4, 2025 /PRNewswire/ -- BPC Instruments AB (publ) ("BPC") announces orders from KU Leuven university in Belgium. The orders include the delivery of several instruments... ► Artikel lesen | |
| 28.05. | Bulletin from the Annual General Meeting of BPC Instruments AB | 1 | Cision News | ||
| 07.05. | BPC Instruments AB: BPC Instruments Annual Report for 2024 | 861 | PR Newswire | LUND, Sweden, May 7, 2025 /PRNewswire/ -- BPC Instruments (publ) hereby publishes the Annual Report for the year 2024. The Annual Report is available as an attached file to this release and... ► Artikel lesen | |
| 07.05. | BPC Instruments AB: BPC Instruments reports results for Q1 2025 | 750 | PR Newswire | LUND, Sweden, May 7, 2025 /PRNewswire/ -- BPC Instruments (publ) hereby publishes the interim report for the period January 1 - March 31, 2025. The interim report is available as an attachment... ► Artikel lesen | |
| 26.02. | BPC Instruments AB: BPC Instruments reports result for year 2024 | 678 | PR Newswire | LUND, Sweden, Feb. 26, 2025 /PRNewswire/ -- BPC Instruments (publ) hereby publishes the year-end report for the year 2024. The year-end report is available as an attached file to this release... ► Artikel lesen | |
| 26.02. | BPC Instruments AB: BPC Instruments reports result for year 2024 | 449 | PR Newswire | LUND, Sweden, Feb. 26, 2025 /PRNewswire/ -- BPC Instruments (publ) hereby publishes the year-end report for the year 2024. The year-end report is available as... ► Artikel lesen | |
| 20.02. | BPC Instruments AB: BPC Instruments receives order from DairyExperts for animal nutrition research | 467 | PR Newswire | LUND, Sweden, Feb. 20, 2025 /PRNewswire/ -- BPC Instruments AB (publ) ("BPC") announces an order of approx. SEK 0.5 million from DairyExperts, a US-based organisation specialising in livestock... ► Artikel lesen | |
| 24.01. | BPC Instruments AB: BPC announces Directed Share Issue to Eiffel Investment Group | 561 | PR Newswire | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 20.12.24 | BPC Instruments AB: Berenberg acquires shares in BPC | 700 | PR Newswire | LUND, Sweden, Dec. 20, 2024 /PRNewswire/ -- BPC Instruments AB (publ) ("BPC") announces that the Berenberg European Micro Cap Fund has acquired 4.8 percent of outstanding shares in BPC via... ► Artikel lesen | |
| 12.12.24 | BPC Instruments AB: BPC Instruments receives orders of 1,1 MSEK for newly launched BPC Air | 745 | PR Newswire | LUND, Sweden, Dec. 12, 2024 /PRNewswire/ -- BPC Instruments AB (publ) ("BPC") is pleased to announce orders from KTH Sweden and University of Texas USA, totaling 1,1 MSEK. These orders include... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUVALENT | 105,88 | -1,97 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,56 | -0,13 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| QIAGEN | 40,380 | +2,38 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,170 | +8,45 % | Recursion (RXRX) Jumps 8% on Bargain-Hunting | ||
| BIONTECH | 83,05 | +0,06 % | Raus aus BioNTech? Rein in Evotec und Vidac Aktie? Was läuft da mit Johnson und Johnson? | Paukenschläge bei Biotechs: Partner Pfizer verkauft seine komplette Beteiligung am deutschen Biotech-Champion BioNTech. Sollten Anleger es genauso machen? Dagegen liefert Vidac Pharma mehr und mehr... ► Artikel lesen | |
| JANUX THERAPEUTICS | 28,800 | +0,73 % | Wolfe Research initiates Janux Therapeutics stock with Peerperform rating | ||
| PRAXIS PRECISION MEDICINES | 169,78 | +3,33 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Participate in Upcoming Fireside Chat | ||
| COGENT BIOSCIENCES | 36,770 | +5,97 % | COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know | ||
| OLEMA PHARMACEUTICALS | 23,190 | +5,36 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| IMMUNOVANT | 22,580 | -0,92 % | Immunovant, Inc. - 8-K, Current Report | ||
| ARCUTIS BIOTHERAPEUTICS | 29,460 | +7,89 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| EVOTEC | 5,206 | +0,58 % | Evotec: Startet jetzt der Turnaround? | ||
| RAPPORT THERAPEUTICS | 27,250 | +1,49 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| IMMUNOME | 18,510 | +5,77 % | Varegacestat-Potenzial: Stephens erhöht Kursziel für Immunome auf 33 US-Dollar | ||
| MINERALYS THERAPEUTICS | 42,000 | +0,33 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen |